Peptides for Weight Loss. What Fits Which Goal in 2026
Medically reviewed by the Rite Aid Health Team · Last updated
- Approved products containing semaglutide or tirzepatide have large controlled weight management trials.
- Tesamorelin has an approved role in reducing excess abdominal fat in adults with HIV and lipodystrophy.
- MOTS-c research examines glucose handling, insulin sensitivity, weight, and waist measurements.
Evidence and status
- Approval status
- Depends on the medication
- Strongest support
- Ranges from approved labeling to preclinical research
- Route context
- Depends on the medication and indication
- Competitive sport
- Check the specific medication
Get the Free Peptide Tracking Toolkit
Start with Weight Loss, then review other peptide categories. Keep the details you verify in the Excel workbook.
Excel workbook
11 worksheets for vials, schedules, labs, storage, and more.
PDF guide
Review providers, products, documents, storage, and travel.
Free download
Useful before or after you start
- Before you start, compare the details that matter and build a focused question list.
- Already using peptides? Keep vials, administration, sites, wellness notes, labs, storage, and travel together.
- Separate your schedule from what actually happened, so important dates are easier to spot.
- Keep your private working copy on your own device.
Confirm your email to receive both downloads and your personal 20% off coupon.
Almost done
We sent the first email to .
Confirm your email to get the toolkit and your 20% off coupon.
We also sent a verification text. Reply YES to confirm your phone number.
-
1
Confirm your email
Open the first email and click the confirmation link.
-
2
Only after step 1
Then the toolkit arrives
We email your Excel workbook and PDF guide right away. Your personal 20% off coupon follows when ordering opens.
The first email should arrive within a minute. Do not see it? Check spam or promotions.
Tell us where to send it
Free, no spam, only peptide news that matters. Unsubscribe anytime.
Approved medicines: forms, trial results, and access
These medicines were studied in separate trials with different populations and statistical approaches. The results are not head-to-head comparisons, and each trial included lifestyle support. Trial estimates use each paper’s primary analysis; dropout and adverse-event patterns differed across studies.
| Treatment | Studied form and dose | Primary trial outcome | Current labeled eligibility | Cost and access |
|---|---|---|---|---|
| Wegovy (semaglutide), oral | 25 mg oral tablet once daily, with lifestyle support. | OASIS 4: adults without diabetes with BMI ≥30, or ≥27 with a weight-related condition; mean body-weight change at 64 weeks was −13.6% with oral semaglutide and −2.2% with placebo in the treatment-policy analysis of a 71-week trial. Primary trial | Adults with obesity, or overweight with at least one weight-related condition, alongside reduced-calorie eating and increased physical activity. Current FDA-approved label | Check Wegovy savings updates These pages collect interest and send availability updates. They do not promise a currently redeemable discount. |
| Wegovy (semaglutide), injection | 2.4 mg injection once weekly, with lifestyle support. | STEP 1: 1,961 adults without diabetes with BMI ≥30, or ≥27 with a weight-related condition; mean body-weight change at 68 weeks was −14.9% with semaglutide and −2.4% with placebo in the treatment-policy analysis. Primary trial | Adults with obesity, or overweight with a weight-related condition; the injection also has an indication for eligible adolescents aged 12 and older with obesity. Current FDA-approved label | Check Wegovy savings updates These pages collect interest and send availability updates. They do not promise a currently redeemable discount. |
| Zepbound (tirzepatide) | 5, 10, or 15 mg injection once weekly, with lifestyle support. | SURMOUNT-1: 2,539 adults without diabetes with BMI ≥30, or ≥27 with a weight-related complication; at 72 weeks, mean body-weight change was −15.0%, −19.5%, and −20.9% with 5, 10, and 15 mg, respectively, versus −3.1% with placebo in the treatment-regimen analysis. Primary trial | Adults with obesity, or overweight with at least one weight-related condition, alongside reduced-calorie eating and increased physical activity. Current FDA-approved label | Check Zepbound savings updates These pages collect interest and send availability updates. They do not promise a currently redeemable discount. |
| Saxenda (liraglutide) | 3 mg injection once daily, with reduced-calorie eating and increased activity. | SCALE Obesity and Prediabetes: 3,731 adults with obesity or overweight plus dyslipidemia or hypertension, without type 2 diabetes; mean body-weight change at 56 weeks was −8.0% with liraglutide and −2.6% with placebo. Primary trial | Adults qualify with a BMI of 30 or higher. Adults with a BMI of 27 or higher qualify with at least one weight-related comorbidity. Pediatric patients ages 12 and older qualify with obesity and body weight above 60 kg. Saxenda is used with reduced-calorie eating and increased physical activity. Current FDA-approved label | Ask a prescriber and pharmacy about coverage and out-of-pocket cost. |
Four kinds of weight-loss options
The most useful first question is where an option sits today. Approved medicines, drugs in clinical trials, indication-specific treatments, and experimental wellness compounds each come with different evidence and access.
FDA-approved weight-management medicines
| Medicine | Approved use and route | Evidence and practical question |
|---|---|---|
| Liraglutide (Saxenda) | Long-term weight reduction in labeled adults and adolescents; daily injection | Approved labeling and controlled human trials. The daily route, contraindications, and long-term plan affect whether treatment is appropriate. |
| Semaglutide (Wegovy) | Long-term weight reduction in labeled populations; weekly injection | Approved labeling and large controlled human trials. Other semaglutide products do not automatically share Wegovy's indication. |
| Tirzepatide (Zepbound) | Long-term weight reduction in labeled adults; weekly injection | Approved labeling and large controlled human trials. Eligibility, adverse effects, cost, and continued treatment all matter. |
Read the current Saxenda label, Wegovy label, and Zepbound label.
Pipeline drugs
| Candidate | Human evidence | Current meaning |
|---|---|---|
| Retatrutide | Controlled phase 2 study and phase 3 development | Promising trial results, but not an FDA-approved or lawfully marketed treatment |
| Survodutide | Controlled phase 2 study | Investigational; a trial result is not prescribing guidance or approval |
| Cagrilintide | Controlled phase 2 dose-finding study | Investigational and not interchangeable with a combination regimen |
An indication-specific treatment
| Medicine | What is approved | Why it sits apart |
|---|---|---|
| Tesamorelin | Reducing excess abdominal fat in adults with HIV and lipodystrophy; formulation-specific daily injection | Approved labeling and controlled trials support that narrow use. The label says it is not for weight management and is weight neutral. |
Experimental wellness compounds
| Compound | Best available support | What it does not establish |
|---|---|---|
| MOTS-c | Cell and animal findings; a recruiting human trial without posted results | Human weight-loss benefit, safety, route, or dose |
| AOD-9604 | FDA review of limited human studies; the larger study did not consistently show weight loss | A proven fat-loss effect or an evidence-based regimen |
| 5-amino-1MQ | Short mouse research; it is a small molecule, not a peptide | Human effectiveness, safety, or dosing |
How the main options work
- GLP-1 medicines slow digestion, reduce appetite, and improve glucose regulation. Tirzepatide adds activity at the GIP receptor.
- Tesamorelin raises growth hormone and IGF-1 through the pituitary. Its trials measured visceral abdominal fat rather than appetite-driven weight loss.
- MOTS-c is studied as a mitochondrial signal involved in cellular energy use, insulin sensitivity, and adaptation to metabolic stress.
People sometimes combine compounds because they target different goals, such as appetite and body composition. The safety and monitoring questions then come from every component in the combination.
Safety changes the decision
Approved GLP-1 and GIP-based weight medicines commonly cause digestive side effects. Their labels also cover serious risks, contraindications, interactions, pregnancy, and dose escalation.
Tesamorelin has different risks, including higher blood sugar and IGF-1. MOTS-c lacks enough human evidence to define a risk profile.
A medicine that fits one person's history may not fit another's. Review relevant conditions, medicines, pregnancy plans, and treatment goals with a licensed clinician.
A useful next step
For appetite and long-term weight management concerns, start with the GLP-1 weight loss readiness quiz.
If the concern is a change in abdominal fat linked with HIV treatment, ask specifically about the Egrifta SV indication.
Get the Free Peptide Tracking Toolkit
Start with Weight Loss, then review other peptide categories. Keep the details you verify in the Excel workbook.
Excel workbook
11 worksheets for vials, schedules, labs, storage, and more.
PDF guide
Review providers, products, documents, storage, and travel.
Free download
Useful before or after you start
- Before you start, compare the details that matter and build a focused question list.
- Already using peptides? Keep vials, administration, sites, wellness notes, labs, storage, and travel together.
- Separate your schedule from what actually happened, so important dates are easier to spot.
- Keep your private working copy on your own device.
Confirm your email to receive both downloads and your personal 20% off coupon.
Almost done
We sent the first email to .
Confirm your email to get the toolkit and your 20% off coupon.
We also sent a verification text. Reply YES to confirm your phone number.
-
1
Confirm your email
Open the first email and click the confirmation link.
-
2
Only after step 1
Then the toolkit arrives
We email your Excel workbook and PDF guide right away. Your personal 20% off coupon follows when ordering opens.
The first email should arrive within a minute. Do not see it? Check spam or promotions.
Tell us where to send it
Free, no spam, only peptide news that matters. Unsubscribe anytime.
Blood work before and during weight loss
People commonly establish a baseline before starting and repeat relevant tests during treatment. The medicine, health history, and product label determine which markers and timing matter most.
- Metabolic Profile includes glucose, liver enzymes, kidney measures, and electrolytes. It does not determine which medicine is right.
- Men's Hormone Health Checkup and Women's Hormone Health Checkup answer broader hormone questions. They are not required for every weight management medicine.
The repeat test creates a comparison with the starting point. Weight, waist measurements, side effects, appetite, and other treatment goals add information that a blood panel cannot show.
Peptide Baseline Measurement Panel
Get your baseline- No doctor visit required
- 2,200+ Quest locations
- Results in 1–2 business days
References
For general education only — not medical advice or a treatment recommendation. Peptides are not a substitute for care from a licensed provider. Talk to a qualified healthcare professional before you start, stop, or change any peptide, medication, or supplement.
FAQ
Semaglutide and tirzepatide products have FDA-approved weight management indications for eligible people. Product, eligibility, dose, and safety requirements differ, so the exact label matters.
No. Egrifta SV is approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. Its label states that it is not indicated for weight loss.
That has not been established in humans. MOTS-c weight and metabolism findings come mainly from cell and animal studies, and there is no FDA-approved MOTS-c product.
Yes. They are peptide-based medicines that act on appetite and glucose pathways. Tirzepatide acts on both GIP and GLP-1 receptors.
“James Bond peptide” is an online nickname for WVE-007. WVE-007 is an investigational GalNAc-siRNA, a targeted RNA-based treatment studied for obesity. It is not a peptide.
Key considerations include the treatment goal, approved indication, medical history, route, side effects, cost, and expected treatment duration. A licensed clinician can assess eligibility.